In clinical studies of adjuvant chemotherapy‐treated and untreated groups, patients with stage III CRC whose tumors overexpressed TP53 experienced significantly shorter survival following 5‐FU‐based chemotherapy than patients whose tumors did not express TP53 with detectable alterations.48, 49. The gene discussed is TP53; the disease is colorectal carcinoma.